Open Forum Infectious Diseases

Papers
(The H4-Index of Open Forum Infectious Diseases is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-10-01 to 2023-10-01.)
ArticleCitations
High-Dose Intravenous Immunoglobulin as a Therapeutic Option for Deteriorating Patients With Coronavirus Disease 2019262
Coronavirus Disease 2019 Treatment: A Review of Early and Emerging Options198
C-Reactive Protein Level May Predict the Risk of COVID-19 Aggravation157
Lessons Learned From the First 10 Consecutive Cases of Intravenous Bacteriophage Therapy to Treat Multidrug-Resistant Bacterial Infections at a Single Center in the United States153
Review: Hydroxychloroquine and Chloroquine for Treatment of SARS-CoV-2 (COVID-19)130
Hope on the Horizon: Novel Fungal Treatments in Development122
Monkeypox: A Contemporary Review for Healthcare Professionals120
Prospective Cohort of Fluvoxamine for Early Treatment of Coronavirus Disease 19114
Postacute COVID-19: An Overview and Approach to Classification107
Long COVID and Post-infective Fatigue Syndrome: A Review101
An “Infodemic”: Leveraging High-Volume Twitter Data to Understand Early Public Sentiment for the Coronavirus Disease 2019 Outbreak99
Risk Factors for Herpes Zoster Infection: A Meta-Analysis96
Serum Iron Level as a Potential Predictor of Coronavirus Disease 2019 Severity and Mortality: A Retrospective Study92
Prolonged and Late-Onset Symptoms of Coronavirus Disease 201986
Characterization of Bacterial and Fungal Infections in Hospitalized Patients With Coronavirus Disease 2019 and Factors Associated With Health Care-Associated Infections84
Prolonged Low-Dose Methylprednisolone in Patients With Severe COVID-19 Pneumonia78
Antiviral Activity and Safety of Darunavir/Cobicistat for the Treatment of COVID-1978
Prevalence of Co-infection at the Time of Hospital Admission in COVID-19 Patients, A Multicenter Study75
Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections74
Olfactory Dysfunction in Coronavirus Disease 2019 Patients: Observational Cohort Study and Systematic Review73
Infectious Complications Following CD19 Chimeric Antigen Receptor T-cell Therapy for Children, Adolescents, and Young Adults71
Changing the Use of HIV Pre-exposure Prophylaxis Among Men Who Have Sex With Men During the COVID-19 Pandemic in Melbourne, Australia68
Coronavirus Disease 2019–Associated Invasive Fungal Infection62
Persistent Symptoms and Association With Inflammatory Cytokine Signatures in Recovered Coronavirus Disease 2019 Patients61
Transmission of SARS-CoV-2 in Public Transportation Vehicles: A Case Study in Hunan Province, China58
CD8+ T-Cell Responses in COVID-19 Convalescent Individuals Target Conserved Epitopes From Multiple Prominent SARS-CoV-2 Circulating Variants57
Tecovirimat for the Treatment of Human Monkeypox: An Initial Series From Massachusetts, United States57
Secondary Bacterial Infections in Critical Ill Patients With Coronavirus Disease 201955
Changes in Body Mass Index and Atherosclerotic Disease Risk Score After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide55
Sources of Vaccine Hesitancy: Pregnancy, Infertility, Minority Concerns, and General Skepticism55
SARS-CoV-2 Serologic Assay Needs for the Next Phase of the US COVID-19 Pandemic Response55
Invasive Aspergillosis as an Under-recognized Superinfection in COVID-1953
Impact of Bamlanivimab Monoclonal Antibody Treatment on Hospitalization and Mortality Among Nonhospitalized Adults With Severe Acute Respiratory Syndrome Coronavirus 2 Infection53
A Distinct Phylogenetic Cluster of Indian Severe Acute Respiratory Syndrome Coronavirus 2 Isolates53
Suboptimal Response to Coronavirus Disease 2019 Messenger RNA Vaccines in Patients With Hematologic Malignancies: A Need for Vigilance in the Postmasking Era52
Monoclonal Antibody Therapy for COVID-19 in Solid Organ Transplant Recipients51
Sexually Transmitted Infection Diagnoses and Access to a Sexual Health Service Before and After the National Lockdown for COVID-19 in Melbourne, Australia48
Fever and Fever of Unknown Origin: Review, Recent Advances, and Lingering Dogma47
SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar47
Prevalence and Healthcare Burden of Fungal Infections in the United States, 201846
Risk of Clinical Severity by Age and Race/Ethnicity Among Adults Hospitalized for COVID-19—United States, March–September 202046
Staphylococcus aureus Bacteremia in Patients Infected With COVID-19: A Case Series45
The Clinical Course of COVID-19 in the Outpatient Setting: A Prospective Cohort Study45
Persistence, Magnitude, and Patterns of Postacute Symptoms and Quality of Life Following Onset of SARS-CoV-2 Infection: Cohort Description and Approaches for Measurement45
SARS-CoV-2 Seroconversion and Viral Clearance in Patients Hospitalized With COVID-19: Viral Load Predicts Antibody Response45
0.060796976089478